Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent Pemetrexed/Cisplatin and Pleural IMRT for Mesothelioma
NCT02639767Phase 1Withdrawn
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pemetrexed and cisplatin in malignant pleural mesothelioma (MPM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Dose Limiting Toxicities at 12 weeks. Planned start Dec 2015; status: withdrawn.
02
Drugs
pemetrexedcisplatin
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT02639767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02639767.